A rapid and precise Reverse Phase High Performance Liquid Chromatographic method has been developed for the validated of Lignocaine and Clotrimazole, in its pure form as well as in ear drops. Chromatography was carried out on a Phenomenex C18 (4.6×250mm) 5µ column using a mixture of Methanol, Acetonitrile and potassium dihydrogen phosphate buffer (50:20:30) as the mobile phase at a flow rate of 1.2 ml/min, the detection was carried out at 220nm. The retention time of the Clotrimazole and Lignocaine was 2.266, 6.349min respectively. The method produce linear responses in the concentration range of 10-60µg/ml of Clotrimazole and 10-60µg/ml of Lignocaine. The method precision for the determination of assay was below 2.0% RSD. The method is useful in the quality control of pharmaceutical formulations.

A new simple, precise, rapid and accurate reverse phase high performance liquid chromatographic method had been developed for estimation of nimorazole in pure and its pharmaceutical dosage form1,2. The chromatographic separation was achieved on inertil ODS 3V 150mmx4.6mm, 5µm particle size column was used with UV detector by using mobile phase containing mixture of phosphate buffer pH 4: methanol (70:30) was used. The flow rate was 1ml/min and effluents were monitored at 300 nm3,4. Chromatogram showed peak correspondence to nimorazole at retention time 4.9 min. the method was linear over the concentration range 5-35 µg/ml. The developed method was validated in according to ICH guidelines.

We have developed two simple accurate and economic UV spectrophotometric methods for the simultaneous estimation of Lornoxicam and Diacerein in bulk and pharmaceutical formulation. The solvent used is methanol and the λ max or the absorption maxima of the Lornoxicam and Diacerein was found to be 382 nm and 341 nm respectively. Two wavelengths were selected at wavelengths 341 nm and isobestic point 274 nm, in absorbance ratio method. The Beer- Lambert’s law followed in the concentration range of 2-10 µg/ml and 10-50 µg/ml for Lornoxicam and Diacerein respectively. These two methods can be used for the analysis of both drugs in pharmaceutical dosage form and quality control study.

The purpose of this study is to assess the knowledge level of Hepatitis B virus (HBV) and Hepatitis C virus (HCV) and human immunodeficiency virus antibodies (anti-HIV) infection in thalasseamia patients (SCA) receiving multiple blood transfusions in Hodeidah city, Republic Yemen. A total of 121 blood samples were collected from patients these attending to the medical department at Yemeni association for patients with thalasseamia and heredity blood, at AL-Salkana hospital in Al-Hodeidah city, between March to September 2016, Screening was carried out by rapid qualitative serologic(RDTs) and enzyme linking immunoassay tests(ELISA). Rapid qualitative serologic tests are used for detected viral hepatitis B surface antigen (HBsAg), Anti-hepatitis C virus (anti-HCV). Enzyme linking immunoassay tests (ELISA) for detected viral hepatitis B surface antigen (HBsAg), Anti-hepatitis C virus (anti-HCV) and human immunodeficiency virus antibodies (anti-HIV). Of the 121 patients participants tested by rapid qualitative serologic tests 1(0.8%) male and 3 (2.5%) female was positive by Hepatitis B virus surface antigen (HBsAg) and 1(1%) male was positive by HCV (anti-HCV). Screening by used ELISA test all specimen for Hepatitis B virus (HBV) and Hepatitis C virus (HCV) and human immunodeficiency virus antibodies (anti-HIV) was negative (0%). In conclusion: the prevalence of HBV, HCV and HIV infection in sickle cell anemia patients is significantly lower than that observed in normal individuals. The results of our study highlights the need for contours regular screening for HBV, HCV and HIV among sickle cell disease patients.

The present study was aimed at developing a reversed phase high performance liquid chromatography (RP-HPLC) method for determination of curcumin (CRM) in plasma and hydrochlorothiazide was used as an internal standard. The separation was achieved by using C-18 column (Qualisil BDS C18, 250 mm x 4.6 mm I.D.) coupled with a guard column of silica, mobile phase was consisting of acetonitrile: water with 0.1% formic acid (40:60 v/v). The flow rate was 0.3 ml/min and the drug was detected using PDA detector at the wavelength of 423 nm. The experimental conditions, including the diluting solvent, mobile phase composition, column saturation and flow rate, were optimised to provide high-resolution and reproducible peaks. The developed method was validated in terms of linearity, recovery, precision, ruggedness, sensitivity (LOD and LOQ) and stability study (short and long-term stabilities, Freeze/thaw stability and post-preparative).